FINWIRES · TerminalLIVE
FINWIRES

SHA:603707

3 stories mentioning SHA:603707Updated 15d ago

Every FINWIRES story that references SHA:603707, newest first.

What's the latest news on SHA:603707?

Asia

China Shares Fall for Second Straight Day on Inflation Worries; Nanjing King-Friend Up 50%

Chinese shares fell for the second straight day on Wednesday as inflation concerns were fueled by rising geopolitical tensions in the Middle East.The Shanghai Composite Index, the main gauge of Chinese stocks, went down 1.0% to 3,941.39. The Shenzhen Component Index fell 1.9% to 13,611.55.Westpac analysts said investors sold off equities in most developed markets, driven by reignited inflation worries stemming from the prospect of additional disruptions in the Strait of Hormuz, Reuters reported.On the domestic front, China discovered a copper-gold deposit in Anhui Province's Xuancheng City. Preliminary assessments of the Chating copper-gold deposit indicate copper resources could exceed several large mines combined, while gold equivalents may top 10 large-scale deposits.In company news, Nanjing King-Friend Biochemical Pharmaceutical (SHA:603707) subsidiary Emerge Bioscience obtained U.S. Food and Drug Administration approval to manufacture adalimumab injection at Kingfriend's manufacturing facility. Shares of the pharmaceutical company fell 5% Wednesday.

Shanghai Composite^SZSESHA:603707
Asia

Nanjing King-Friend Biochemical Pharmaceutical Gets US FDA Nod for Drug Manufacturing Site; Shares Down 5%

Nanjing King-Friend Biochemical Pharmaceutical (SHA:603707) subsidiary Emerge Bioscience obtained U.S. Food and Drug Administration approval to manufacture adalimumab injection at Kingfriend's manufacturing facility.The biosimilar, sold under the brand YUSIMRY, was originally approved for nine indications including rheumatoid arthritis, Crohn's disease and psoriasis, according to a Wednesday filing with the Shanghai bourse.Shares of the pharmaceutical company declined 5% in recent trade.

SHA:603707
Asia

Tonghua Dongbao Pharmaceutical, Nanjing King-Friend Secure US Approval for Insulin Aspart Injection; Shares Up 2%

Tonghua Dongbao Pharmaceutical (SHA:600867) said its insulin aspart injection, co-developed with Nanjing King-Friend Pharmaceutical (SHA:603707), received U.S. Food and Drug Administration biologics license application approval, according to a Tuesday filing with the Shanghai Stock Exchange.The injection is indicated to improve blood glucose control through subcutaneous injection, the filing said.Shares of Dongbao rose 2% during afternoon trading on Tuesday.

SHA:600867SHA:603707

Track with the FINWIRES app suite